Richard J Larkin Net Worth

The estimated Net Worth of Richard J Larkin is at least $59 Tysiąc dollars as of 2 May 2016. Richard Larkin owns over 23,217 units of Chembio Diagnostics stock worth over $24,036 and over the last 20 years Richard sold CEMI stock worth over $35,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Larkin CEMI stock SEC Form 4 insiders trading

Richard has made over 2 trades of the Chembio Diagnostics stock since 2014, according to the Form 4 filled with the SEC. Most recently Richard exercised 23,217 units of CEMI stock worth $100,994 on 2 May 2016.

The largest trade Richard's ever made was exercising 23,217 units of Chembio Diagnostics stock on 2 May 2016 worth over $100,994. On average, Richard trades about 1,384 units every 33 days since 2004. As of 2 May 2016 Richard still owns at least 52,253 units of Chembio Diagnostics stock.

You can see the complete history of Richard Larkin stock trades at the bottom of the page.

What's Richard Larkin's mailing address?

Richard's mailing address filed with the SEC is 3661 HORSEBLOCK ROAD, , MEDFORD, NY, 11763.

Insiders trading at Chembio Diagnostics

Over the last 20 years, insiders at Chembio Diagnostics have traded over $909,824 worth of Chembio Diagnostics stock and bought 3,754,893 units worth $1,696,058 . The most active insiders traders include Credit Advisors, Llcpercept..., Lawrence A. Siebert oraz Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of $36,203. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth $109,552.

What does Chembio Diagnostics do?

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Complete history of Richard Larkin stock trades at Chembio Diagnostics

Chembio Diagnostics executives and stock owners

Chembio Diagnostics executives and other stock owners filed with the SEC include:

• Javan Esfandiari,
  Exec. VP and Chief Science & Technology Officer
• Richard L. Eberly,
  Pres, CEO & Director
• Javan Esfandiari,
  Executive Vice President, Chief Scientific And Technology Officer
• Neil Goldman,
  Chief Financial Officer, Executive Vice President
• Katherine Davis,
  Independent Director
• John Potthoff,
  Independent Director
• Gail Page,
  Executive Chairman of the Board
• Mary Polan,
  Independent Director
• Lynn Lewis,
  Investor Relations Contact Officer
• Chuck Caso,
  Vice President of Sales and Marketing for North America
• Richard Eberly,
  President, Chief Executive Officer, Director
• Stella Rivera,
  VP of HR
• Atif Rizvi,
  VP of Fin.
• Dr. Konstantin Lyashchenko,
  Research Director of Chembio Diagnostic Systems Inc
• Charles Caso,
  VP of Sales & Marketing
• Paul J. Angelico,
  VP of Global Operations
• Peter Kissinger,
  Director
• Richard J Larkin,
  Chief Financial Officer
• Barbara A De Buono,
  Director
• John J Iii Sperzel,
  CEO
• Robert L Aromando,
  Sr VP, Commercial Operations
• Alan Carus,
  Director
• Lawrence A. Siebert,
  President
• Leslie Teso Lichtman,
  
• Norman H Pessin Brian L. Pe...,
  
• Gary Meller,
  Director
• Sharon W Klugewicz,
  Chief Operating Officer
• David Gyorke,
  See Remarks
• Robert Passas,
  See Remarks
• Avi Pelossof,
  Vice President
• Gerald A Eppner,
  Director
• James D Merselis,
  Director
• Capital Master Llc Crestvie...,
  
• David Acheson,
  
• Credit Advisors, Llcpercept...,
  
• David William Bespalko,
  
• Lawrence J. Steenvoorden,
  See remarks
• Charles Caso,
  See Remarks
• Paul Angelico,
  See remarks